HilleVax

About HilleVax

HilleVax is dedicated to advancing the development of a vaccine to protect against norovirus infection, which is the most common viral cause of acute gastroenteritis worldwide.

Products & Services

Norovirus Vaccine:A vaccine in development to protect against norovirus, responsible for over 90% of epidemic non-bacterial outbreaks of gastroenteritis, causing approximately 700 million cases and 200,000 deaths annually.

Specialties

Vaccine Development Norovirus Prevention

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 115000000 MR: - FA: $115.0 million FAN: 115000000	D: 2023-09-25 FD: 2023-09-25	4 investors

Public Offering Latest

2023-09-25

$115.0M

4 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

T

Tadataka Yamada

World-Renowned Physician-Scientist

M

Maurice Hilleman

Father of Modern Vaccines

J

Jeri Hilleman

Former Chief Financial Officer and Board Member

R

Rob Hershberg

Co-Founder, President, Chief Executive Officer and Chairman of the Board of Directors

A

Astrid Borkowski

Chief Medical Officer

P

Paul Bavier

General Counsel, Secretary and Chief Administrative Officer

View 13 more team members with Pro

Unlock Full Team Directory

Recent News

HilleVax Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised